AstraZeneca to supply 400 million of potential vaccine to Europe

▴ astrazeneca-supply-400-million-potential-vaccine-europe
Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon

UK Pharma company AstraZeneca Plc has come in a contract with European governments to provide its potential vaccine against the Coronavirus to assist combat the pandemic.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company reportedly said on Saturday, adding that it had been looking to expand the manufacturing of the vaccine, which it said it might provide for no profit during the pandemic. The vaccine remains in clinical trials. If the trial results convince regulators the vaccine is safe and effective, deliveries would be expected to start out by 2020 end.
The deal thus inscribes that Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon.

"This will make sure that hundreds of millions of people in Europe will have access to the present vaccine, in fact, if it works and that we will know that by summer-end," the company's chief executive, Pascal Soriot was quoted as saying to the journalists. He said he has "good hope" that it'll work, supported initial data.
The alliance "will work alongside the European Commission and other countries in Europe to make sure everybody across Europe is provided with the vaccine," he said.
"We have a really self-sufficient supply chain for Europe" with manufacturers lined up within the Netherlands, Germany, Italy, and Italy, among others, he further said.


The vaccines are for all EU member states. The four nations that agreed the deal can pay for the entire amount, which has not been disclosed, and therefore the scheme allows other countries to hitch it under equivalent conditions, a source from the Italian health ministry said.
Apparently, China, Brazil, Japan, and Russia have also shown interest in this vaccine.
It has got the green signal from The British Medicines and Healthcare products regulatory authority (MHRA) kick start the phase III clinical trial of the vaccine after studies suggest sufficient efficacy and safety, Soriot reportedly said.
At a gathering of EU Health Ministers on Friday, IVA apparently agreed to merge its activities with those of the EU Commission, Germany's Health Ministry said.
It has agreed on the manufacturing of manufacturing 2 billion doses of the vaccine to serve its target beneficiaries along with two Bill Gates-backed ventures and a $1.2 billion agreement with the United States government.
The deal will add an extra 100 million doses to the two billion already committed by the group, AstraZeneca said.
There are not any approved vaccines or treatments for COVID-19, the highly contagious respiratory disease caused by the novel coronavirus.
"Many countries within the world have already secured vaccines, Europe has not yet. The rapid coordinated action of a gaggle of member states will create added value for all EU citizens during this crisis," Italian Health Minister Roberto Speranza was quoted as saying

Tags : #Coronavirus #Vaccine #Astrazeneca #Europe #China #Brazil #BillGates

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026